Mexicor injection 50mg / ml 2 ml ampoules 10 pcs


Mexicor injection 50mg / ml 2 ml ampoules 10 pcs



Active substance:
in 1 ml solution contains 50 mg emoxypine
succinic acid – 5.0 mg Disodium edetate – 0.1 mg Water for injection – up to 1.0 ml.
clear, colorless or slightly colored liquid.
Product form:
Solution for intravenous and intramuscular administration of 50 mg / ml. In 2 ml vials of glass with a light-shielding colored ring fracture or color point of fracture. 5 vials are placed in blisters of PVC film and aluminum foil or non-foil (a pallet).
2 blisters with ampoules of 2 ml, together with instructions for use placed in a pile of cardboard. On each tube is applied a self-adhesive label.
Hypersensitivity to the drug, the liver and kidney function, age of 18 years (effectiveness and safety have not been established), pregnancy, breastfeeding.
50 mg / ml
The drug is used in the treatment of:
acute myocardial infarction (the first day);
acute cerebrovascular accidents;
traumatic brain injury, the effects of traumatic brain injury;
vegetative syndrome (neuro) dystonia;
mild cognitive disorders of atherosclerotic;
anxiety disorders in neurotic and neurosis-like states;
relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetative-vascular disorders;
acute intoxication antipsychotics.
Interaction with other drugs
Potentiates the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa) nitrate. It reduces the toxic effects of ethanol.
Symptoms: sleep disturbance (insomnia), in some cases, drowsiness; when administered intravenously in rare cases minor and short-term (1.5-2 hr) increasing blood pressure.
Treatment: the development of symptoms of overdose usually do not require the use of tools docked, these symptoms of sleep disorders disappear on their own within a day. In severe cases it is recommended to use one of hypnotics and antianxiety drugs for oral administration (10 mg nitrazepam, oxazepam, diazepam 10 mg or 5 mg). When excessive increase in blood pressure is applied antihypertensives blood pressure under control.
pharmachologic effect
Pharmacological group:
anti-oxidant agent.
Meksikor® has antioxidant, antihypoxic, membrano, nootropic, stressprotektivnoe, anticonvulsant, anxiolytic action.
The preparation increases the body’s major resistance to the effects of disturbing factors, for kislorodzavisimym pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, alcohol intoxication and antipsychotic agents (neuroleptics)).
The mechanism of action caused Meksikora® antihypoxic, antioxidative and membranoprotektornym action ethylmethylhydroxypyridine succinate and succinic acid in its composition.
Preparation improves the functional state of ischemic myocardium in myocardial infarction improves the contractility of the heart function, and reduces the appearance of systolic and diastolic left ventricular dysfunction.
The preparation normalizes the metabolic processes in the ischemic myocardium reduces the zone of necrosis, restores and / or improves the electrical activity and contractility of the myocardium and increases collateral blood supply, activating energosinteziruyuschie processes in the area of ​​ischemia and promoting preservation of the integrity of cardiomyocytes and maintain their functional activity.
It increases anti-anginal activity nitropreparatov, improves blood rheology, reduces the effects of reperfusion syndrome in acute coronary insufficiency.
Preparation improves the cerebral circulation and cerebral metabolism, improves microcirculation and blood rheology, prevents the decrease in cerebral blood flow after ischemia reperfusion period. It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Meksikor® prevents post-ischemic drop in utilization of glucose and oxygen by the brain and prevents the progressive accumulation of lactate.
The drug inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein improves the structure and function of cell membranes. Modulates the activity of membrane enzymes – calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase receptor complexes (benzodiazepine, gamma aminomyaslyany, acetylcholine) that enhances their ability to bind to ligands, helps preserve the structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Meksikor® increases the concentration of dopamine in the brain.
Meksikor® compensatory causes increased activity of aerobic glycolysis and thereby reducing the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with increasing content of adenosine triphosphate (ATP) and creatine phosphate energosinteziruyuschih activation of mitochondrial functions, stabilization of cell membranes.
When administered intravenously, the drug quickly (within 0.5-1.5 hours) proceeds from the bloodstream to organs and tissues and therefore its concentration in unmodified form rapidly decreases. When administered intramuscularly at therapeutic doses, the maximum concentration of drug in blood plasma is achieved after 30-40 minutes and is 2.5-3 mg / ml, while its metabolites determined in plasma over 7.9 hours.
Excretion of the drug from the body is urinary in glyukuronokonyugirovannoy form and in small quantities in an unmodified form.
Conditions of supply of pharmacies
On prescription.
special instructions
during acute myocardial infarction, acute (ischemic stroke) and chronic (encephalopathy), cerebral circulatory disorders after completion parenteral administration to maintain therapeutic effect achieved, it is recommended to continue applying Meksikor® drug in the dosage form: capsules of 100 mg 3 times a day. The duration of therapy is determined by the doctor.
Storage conditions
Store in the dark and away from children at a temperature not higher than 25 ° C.
Dosing and Administration
Intramuscular (i / m) or intravenously (w / w) (bolus or infusion). When the infusion method of administering the drug should be diluted in 0.9% sodium chloride solution.
Chip Meksikor® introduced slowly over 5-7 minutes, dropwise – at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
In acute myocardial infarction in the complex therapy administered Meksikor® / v or v / m for 14 days on standard therapy of myocardial infarction, comprising nitrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, thrombolytic agents, anticoagulant and antiplatelet agents and symptomatic agents indicated.
During the first 5 days, for maximum effect, the drug is desirably administered in / in, in the next 9 days may be administered in Meksikor® / m.
Intravenous drug produced by drip infusion slowly (to avoid side-effects), 0.9% sodium chloride solution or 5% dextrose (glucose) in a volume of 100-150 ml for 30-90 min. If necessary, may slow jet / in a formulation of at least 5 minutes.
Introduction formulation (w / w or w / o) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg / kg body weight per day, single dose – 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single – 250 mg.
In acute stroke (ischemic stroke) Meksikor® used in the treatment in the first 10-14 days / drip 200-500 mg 2-4 times a day, then the / m, 200-250 mg 2-3 times a day for 2 weeks.
In the future, if necessary, you can go to the reception of the drug inside (on doctor’s advice).
In traumatic brain injury or consequences of traumatic brain injury Meksikor® applied for 10-15 days / drip 200-500 mg 2-4 times a day.
In vascular encephalopathy in phase Meksikor® decompensation used on / in bolus or infusion in a dose of 200-500 mg 1-2 times a day for 14 days. Then / m to 100-250 mg / day. within the next two weeks.
In the future, if necessary, you can go to the reception of the drug inside (on doctor’s advice).
For ESP preventing vascular encephalopathy introducing drug / m at a dose of 200-250 mg 2 times a day for 10-14 days.
When neurocirculatory dystonia, neurosis and neurotic states introducing drug / m at 50-400 mg per day for 14 days.
In mild cognitive impairment in the elderly and in anxiety disorders, drug use / m at a dose of 100-300 mg per day for 14-30 days.
When alcohol withdrawal syndrome Meksikor® introducing / m or / drip in a dose of 200-500 mg 2-3 times a day for 5-7 days.
In acute intoxication antipsychotics preparation is administered in / in a dose of 200-500 mg per day for 7-14 days.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review